

Accepted Manuscript

On the use of group sequential study designs for the test of bioequivalence for complicated products

Rajesh Krishna, Wen-Lin Luo, Patrick J. Larson, Paul H. Fackler



PII: S0022-3549(17)30369-6

DOI: [10.1016/j.xphs.2017.05.015](https://doi.org/10.1016/j.xphs.2017.05.015)

Reference: XPHS 818

To appear in: *Journal of Pharmaceutical Sciences*

Received Date: 17 February 2017

Revised Date: 28 April 2017

Accepted Date: 12 May 2017

Please cite this article as: Krishna R, Luo WL, Larson PJ, Fackler PH, On the use of group sequential study designs for the test of bioequivalence for complicated products, *Journal of Pharmaceutical Sciences* (2017), doi: 10.1016/j.xphs.2017.05.015.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Accepted for publication in Journal of Pharmaceutical Sciences as a Note

On the use of group sequential study designs for the test of bioequivalence for complicated products

Rajesh Krishna^{1,2}, Wen-Lin Luo^{1,3}, Patrick J. Larson¹, and Paul H. Fackler¹

¹Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ

Address correspondence to:

²Rajesh Krishna, PhD, FCP

Distinguished Scientist

Merck Research Laboratories

Translational Medicine Research Centre

MSD International GmbH (Singapore)

8 Biomedical Grove,

Block A, Neuros Building, #05-01

Singapore 138665

Phone: +65-63058463

Email: rajesh_krishna@merck.com

³Current address: Novartis Pharmaceuticals, Inc., East Hanover, NJ

Funding Statement

Funding for this study was provided by Merck & Co., Inc., Kenilworth, New Jersey, USA.

Conflicts of Interest

The study was sponsored by Merck & Co., Inc, Kenilworth, New Jersey, USA. Authors who are employees of Merck & Co., Inc, Kenilworth, New Jersey, USA may own stock or stock options in the company.

Keywords: bioequivalence, triple FDC, endpoints, simulation

Download English Version:

<https://daneshyari.com/en/article/8513841>

Download Persian Version:

<https://daneshyari.com/article/8513841>

[Daneshyari.com](https://daneshyari.com)